|6.88 2.68 (63.81%)||12-08 16:00|
|Targets||6-month :||13.36||1-year :||15.6|
|Resists||First :||11.43||Second :||13.36|
|Supports||First :||5.61||Second :||2|
|MAs||MA(5) :||4.16||MA(20) :||2.89|
|MA(100) :||4.37||MA(250) :||0|
|MACD||MACD :||0.3||Signal :||-0.1|
|%K %D||K(14,3) :||58.5||D(3) :||55.5|
|52-week||High :||11.43||Low :||2|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ INTS ] has closed above the upper band by 31.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 0% narrower than normal.
|If tomorrow:||Open lower||Open higher|
|High:||11.45 - 11.5||11.5 - 11.53|
|Low:||6.2 - 6.23||6.23 - 6.25|
|Close:||6.83 - 6.88||6.88 - 6.92|
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||14 (M)|
|Shares Float||8 (M)|
|Held by Insiders||15.9 (%)|
|Held by Institutions||0 (%)|
|Shares Short||4 (K)|
|Shares Short P.Month||3 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||1.15|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-45.3 %|
|Return on Equity (ttm)||-151.8 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-8 (M)|
|Levered Free Cash Flow||-6 (M)|
|Price to Book value||5.93|
|Price to Sales||0|
|Price to Cash Flow||-11.96|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|